50.9
[1]. Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 01 Mar 9;16:1-11.
[]. Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-76070 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 011 Aug;51(8):1177-85.
[]. Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 010 Dec;1(1):911-0.
[]. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-76070) in individuals with amyotrophic lateral sclerosis. Nat Med. 011 Nov 0;17(1):165-6.
[5]. Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 01 Jan;1(1):-51.
H0-H15-H19-H5
P61-P6-P70-P71-P80-P0+P5-P0+P0-P05+P51+P8-P0-P6+P6-P0+P-P05-P501